1
Home
Companies

Deciphera Pharmaceuticals

#4165

Rank

$2.21B

Marketcap

US United States

Country

Deciphera Pharmaceuticals
Leadership team

Mr. Steven L. Hoerter (Pres, CEO & Director)

Dr. Daniel L. Flynn Ph.D. (Exec. VP, Chief Scientific Officer & Founder)

Mr. Thomas Patrick Kelly J.D. (Exec. VP, CFO & Treasurer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
Waltham, Massachusetts, United States
Established
2003
Company Registration
SEC CIK number: 0001654151
Revenue
100M - 500M
Traded as
DCPH
Social Media
URL
https://www.deciphera.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
History

Deciphera was incorporated in 2015 and has since executed a rapid progression of drug candidates into clinical development. The Company's investigational therapy portfolio currently consists of three clinical-stage compounds, DCC-2618, rebastinib and ripretinib, which are being evaluated in multiple indications and line settings. The company is advancing a broad clinical development program including several ongoing late-stage clinical trials.

Mission
Our mission is to discover, develop and commercialize innovative chemotherapy treatments to improve the lives of cancer patients worldwide by providing them with new therapeutic options.
Vision
Our vision is to become a leader in small molecule drug development, so that cancer patients can have access to new treatment options.
Key Team

Mr. Daniel C. Martin (Sr. VP & Chief Commercial Officer)

Mr. Jeffrey M. Held J.D. (Sr. VP & Gen. Counsel)

Dr. Stephen B. Ruddy Ph.D. (Sr. VP & Chief Technical Officer)

Dr. Matthew L. Sherman M.D. (Exec. VP & Chief Medical Officer)

Ms. Lisa Amaya Price (Sr. VP & Chief HR Officer)

Ms. Jama Pitman (Sr. VP of Regulatory, Quality & Portfolio Management)

Jennifer Larson (Sr. VP of Fin. & Investor Relations)

Recognition and Awards
In 2020, Deciphera received the ASTRO Innovation Award for its commitment to developing meaningful therapies for cancer patients.
References

https://in.investing.com/equities/deciphera-pharmaceuticals

https://finance.yahoo.com/quote/DCPH/profile?p=DCPH

https://www.crunchbase.com/organization/deciphera-pharmaceuticals

https://sec.report/CIK/0001654151

https://companiesmarketcap.com/

https://www.deciphera.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Deciphera Pharmaceuticals
Leadership team

Mr. Steven L. Hoerter (Pres, CEO & Director)

Dr. Daniel L. Flynn Ph.D. (Exec. VP, Chief Scientific Officer & Founder)

Mr. Thomas Patrick Kelly J.D. (Exec. VP, CFO & Treasurer)

Products/ Services
Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics
Number of Employees
100 - 500
Headquarters
Waltham, Massachusetts, United States
Established
2003
Company Registration
SEC CIK number: 0001654151
Revenue
100M - 500M
Traded as
DCPH
Social Media
URL
https://www.deciphera.com